1. Home
  2. SPRO vs PDSB Comparison

SPRO vs PDSB Comparison

Compare SPRO & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • PDSB
  • Stock Information
  • Founded
  • SPRO 2013
  • PDSB 2005
  • Country
  • SPRO United States
  • PDSB United States
  • Employees
  • SPRO N/A
  • PDSB N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • PDSB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPRO Health Care
  • PDSB Health Care
  • Exchange
  • SPRO Nasdaq
  • PDSB Nasdaq
  • Market Cap
  • SPRO 45.7M
  • PDSB 43.1M
  • IPO Year
  • SPRO 2017
  • PDSB N/A
  • Fundamental
  • Price
  • SPRO $0.75
  • PDSB $1.08
  • Analyst Decision
  • SPRO Buy
  • PDSB Strong Buy
  • Analyst Count
  • SPRO 4
  • PDSB 3
  • Target Price
  • SPRO $5.00
  • PDSB $10.00
  • AVG Volume (30 Days)
  • SPRO 218.6K
  • PDSB 281.8K
  • Earning Date
  • SPRO 05-14-2025
  • PDSB 05-14-2025
  • Dividend Yield
  • SPRO N/A
  • PDSB N/A
  • EPS Growth
  • SPRO N/A
  • PDSB N/A
  • EPS
  • SPRO N/A
  • PDSB N/A
  • Revenue
  • SPRO $47,977,000.00
  • PDSB N/A
  • Revenue This Year
  • SPRO N/A
  • PDSB N/A
  • Revenue Next Year
  • SPRO N/A
  • PDSB N/A
  • P/E Ratio
  • SPRO N/A
  • PDSB N/A
  • Revenue Growth
  • SPRO N/A
  • PDSB N/A
  • 52 Week Low
  • SPRO $0.51
  • PDSB $0.85
  • 52 Week High
  • SPRO $1.72
  • PDSB $4.42
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 54.69
  • PDSB 45.37
  • Support Level
  • SPRO $0.51
  • PDSB $1.00
  • Resistance Level
  • SPRO $0.83
  • PDSB $1.17
  • Average True Range (ATR)
  • SPRO 0.08
  • PDSB 0.11
  • MACD
  • SPRO 0.01
  • PDSB 0.01
  • Stochastic Oscillator
  • SPRO 76.85
  • PDSB 54.65

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Share on Social Networks: